COVID-19 mRNA vaccine
Sponsors
Stemirna Therapeutics, CanSino Biologics Inc., Vaccine Company, Inc., GlaxoSmithKline, CastleVax Inc.
Conditions
COVID-19COVID-19 PandemicRespiratory Syncytial Virus InfectionsSARS-CoVSARS-CoV-2
Phase 1
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
CompletedNCT05144139
Start: 2021-12-03End: 2022-11-11Updated: 2022-12-28
Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
CompletedNCT05373485
Start: 2022-05-17End: 2022-08-08Updated: 2024-12-04
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
CompletedNCT05938075
Start: 2023-08-04End: 2024-07-25Updated: 2024-12-10
Phase 2
Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
CompletedNCT05373472
Start: 2022-07-06End: 2022-09-21Updated: 2024-12-04
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RecruitingNCT07215520
Start: 2025-11-03End: 2026-08-19Target: 200Updated: 2025-11-06
Phase 3
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
CompletedNCT06374394
Start: 2024-04-29End: 2025-03-31Updated: 2025-12-26
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
RecruitingNCT07655180
Start: 2026-06-08End: 2026-08-01Target: 210Updated: 2026-06-17